ATE490778T1 - Verwendung von äd-mealaü3-äetvalü4-ciclosporin zur behandlung von hepatitis-c-infektion - Google Patents

Verwendung von äd-mealaü3-äetvalü4-ciclosporin zur behandlung von hepatitis-c-infektion

Info

Publication number: ATE490778T1
Authority: AT; Austria
Prior art keywords: treatment; infection; äetvalü4; mealaü3; ciclosporin
Prior art date: 2004-10-01

Application number

AT05791430T

Other languages

English (en)

Inventor

Pietro Scalfaro

Jean-Maurice Dumont

Gregoire Vuagniaux

Rolland-Yves Mauvernay

Original Assignee

Debiopharm Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-10-01

Filing date

2005-10-03

Publication date

2010-12-15

2005-10-03 Application filed by Debiopharm Sa filed Critical Debiopharm Sa

2010-12-15 Application granted granted Critical

2010-12-15 Publication of ATE490778T1 publication Critical patent/ATE490778T1/de

Links

229960001265 ciclosporin Drugs 0.000 title abstract 2
208000005176 Hepatitis C Diseases 0.000 title 1
208000010710 hepatitis C virus infection Diseases 0.000 title 1
239000013543 active substance Substances 0.000 abstract 2
102000001493 Cyclophilins Human genes 0.000 abstract 1
108010068682 Cyclophilins Proteins 0.000 abstract 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
229930105110 Cyclosporin A Natural products 0.000 abstract 1
108010036949 Cyclosporine Proteins 0.000 abstract 1
230000027455 binding Effects 0.000 abstract 1
229930182912 cyclosporin Natural products 0.000 abstract 1
230000001506 immunosuppresive effect Effects 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Virology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

AT05791430T 2004-10-01 2005-10-03 Verwendung von äd-mealaü3-äetvalü4-ciclosporin zur behandlung von hepatitis-c-infektion ATE490778T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IB2004003205		2004-10-01
PCT/IB2005/002940 WO2006038088A1 (en)	2004-10-01	2005-10-03	Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3-[etval]4-cyclosporin

Publications (1)

Publication Number	Publication Date
ATE490778T1 true ATE490778T1 (de)	2010-12-15

Family

ID=34959441

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05791430T ATE490778T1 (de)	2004-10-01	2005-10-03	Verwendung von äd-mealaü3-äetvalü4-ciclosporin zur behandlung von hepatitis-c-infektion

Country Status (29)

Country	Link
US (3)	US7439227B2 (de)
EP (1)	EP1793844B1 (de)
JP (1)	JP4892486B2 (de)
KR (1)	KR101191833B1 (de)
CN (1)	CN101056648B (de)
AT (1)	ATE490778T1 (de)
AU (1)	AU2005290984B2 (de)
BR (1)	BRPI0515494A (de)
CA (1)	CA2580448C (de)
CY (1)	CY1114594T1 (de)
DE (1)	DE602005025232D1 (de)
DK (1)	DK1793844T3 (de)
EA (1)	EA012650B1 (de)
ES (1)	ES2357587T3 (de)
GE (1)	GEP20104960B (de)
HR (1)	HRP20110169T1 (de)
IL (1)	IL182362A0 (de)
MA (1)	MA28950B1 (de)
MX (1)	MX2007003387A (de)
NZ (1)	NZ554412A (de)
PL (1)	PL1793844T3 (de)
PT (1)	PT1793844E (de)
RS (1)	RS51614B (de)
SG (1)	SG139750A1 (de)
SI (1)	SI1793844T1 (de)
TN (1)	TNSN07084A1 (de)
UA (1)	UA88484C2 (de)
WO (1)	WO2006038088A1 (de)
ZA (1)	ZA200702610B (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0320638D0 (en)	2003-09-03	2003-10-01	Novartis Ag	Organic compounds
US7671017B2 (en)	2004-07-14	2010-03-02	Novartis Ag	Use of a combination of cyclosporine and pegylated interferon for treating hepatitis C (HCV)
US7196161B2 (en)	2004-10-01	2007-03-27	Scynexis Inc.	3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
ES2314731T3 (es)	2004-11-22	2009-03-16	Astellas Pharma Inc.	Analogo de ciclosporina.
AU2005322241B2 (en) *	2004-12-23	2010-02-18	Novartis Ag	Compounds for flaviviridae treatment
WO2006071619A1 (en)	2004-12-23	2006-07-06	Novartis Ag	Compositions for hcv treatment
AU2006259348B2 (en) *	2005-06-17	2010-07-22	Novartis Ag	Use of sanglifehrin in HCV
JP5517454B2 (ja)	2005-09-30	2014-06-11	スシネキスインク	Ｃ型肝炎感染の治療及び予防のための方法及び医薬組成物
EP1931696B1 (de)	2005-09-30	2011-02-16	Scynexis, Inc.	Arylalkyl- und heteroarylalkyl-derivate von cyclosporin a bei der behandlung und vorbeugung einer virusinfektion
PT1957518E (pt)	2005-10-26	2016-02-26	Astellas Pharma Inc	Novos compostos peptídicos cíclicos
EP2007789B1 (de)	2006-04-11	2015-05-20	Novartis AG	Spirozyklische HCV/HIV-Hemmer und ihre Verwendung
EP2023918B1 (de)	2006-05-19	2011-03-23	Scynexis, Inc.	Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
CA2665415A1 (en) *	2006-10-12	2008-04-17	Novartis Ag	Use of modified cyclosporins
WO2008069917A2 (en)	2006-11-20	2008-06-12	Scynexis, Inc.	Novel cyclic peptides
KR20100017547A (ko)	2007-05-02	2010-02-16	아스텔라스세이야쿠 가부시키가이샤	신규 시클릭 펩티드 화합물
US8394763B2 (en)	2007-09-26	2013-03-12	Oregon Health & Science University	Cyclic undecapeptides and derivatives as multiple sclerosis therapies
WO2009098533A1 (en) *	2008-02-08	2009-08-13	Debiopharm Sa	Non -immunosuppressive cyclosporin for the treatment of muscular dystrophy
US20090306033A1 (en) *	2008-06-06	2009-12-10	Keqiang Li	Novel cyclic peptides
CN102083852A (zh)	2008-06-06	2011-06-01	西尼克斯公司	环孢菌素类似物及其在治疗hcv感染中的应用
CN102202679B (zh)	2008-11-06	2014-05-07	帝柏奥研究制药有限公司	环十一缩酚酸肽化合物及其作为药物的用途
EP2376524B1 (de)	2008-12-31	2017-03-15	Cypralis Limited	Derivate von cyclosporin a
KR20110111321A (ko)	2009-01-30	2011-10-10	이난타 파마슈티칼스, 인코포레이티드	Ｃ형 간염을 예방하거나 치료하기 위한 사이클로스포린 유사체
US8481483B2 (en)	2009-02-19	2013-07-09	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
US20110182850A1 (en)	2009-04-10	2011-07-28	Trixi Brandl	Organic compounds and their uses
US8512690B2 (en)	2009-04-10	2013-08-20	Novartis Ag	Derivatised proline containing peptide compounds as protease inhibitors
US8685917B2 (en)	2009-07-09	2014-04-01	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
US8349312B2 (en)	2009-07-09	2013-01-08	Enanta Pharmaceuticals, Inc.	Proline substituted cyclosporin analogues
US8367053B2 (en)	2009-07-09	2013-02-05	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
WO2011063076A1 (en)	2009-11-19	2011-05-26	Itherx Pharmaceuticals, Inc.	Methods of treating hepatitis c virus with oxoacetamide compounds
US20110144005A1 (en)	2009-12-09	2011-06-16	Scynexis, Inc.	Novel cyclic peptides
US8623814B2 (en)	2010-02-23	2014-01-07	Enanta Pharmaceuticals, Inc.	Antiviral agents
WO2011141891A1 (en)	2010-05-12	2011-11-17	Debio Recherche Pharmaceutique S.A.	Use of cycloundecadepsipeptide compounds
WO2012009715A2 (en)	2010-07-16	2012-01-19	S&T Global Inc.	Novel cyclosporin derivatives for the treatment and prevention of a viral infection
US9573978B2 (en)	2010-08-12	2017-02-21	S&T Global, Inc.	Cyclosporin derivatives for the treatment and prevention of a viral infection
CN103179974A (zh) *	2010-10-05	2013-06-26	诺华有限公司	丙型肝炎病毒感染的新疗法
JP5909495B2 (ja)	2010-10-08	2016-04-26	ノバルティスアーゲー	スルファミドｎｓ３阻害剤のビタミンｅ製剤
CA2818067A1 (en) *	2010-11-30	2012-06-07	Novartis Ag	New treatments of hepatitis c virus infection
US9890198B2 (en)	2010-12-03	2018-02-13	S&T Global Inc.	Cyclosporin derivatives and uses thereof
JO3337B1 (ar) *	2010-12-13	2019-03-13	Debiopharm Sa	تركيبات صيدلية تشمل أليسبوريفير
AU2012233644A1 (en)	2011-03-31	2013-09-12	Novartis Ag	Alisporivir to treat Hepatitis C virus infection
AU2012237295A1 (en) *	2011-04-01	2013-09-19	Novartis Ag	Treatment for infection with Hepatitis B virus alone or in combination with Hepatitis Delta virus and associated liver diseases
CN103648516A (zh)	2011-04-13	2014-03-19	诺华股份有限公司	使用阿拉泊韦治疗丙型肝炎病毒感染
RU2014116988A (ru) *	2011-09-27	2015-11-10	Новартис Аг	Алиспоривир для лечения инфекции, вызванной вирусом гепатита с
DE202012012955U1 (de)	2011-10-21	2014-07-14	Abbvie Inc.	Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
US8466159B2 (en)	2011-10-21	2013-06-18	Abbvie Inc.	Methods for treating HCV
EP2583677A3 (de)	2011-10-21	2013-07-03	Abbvie Inc.	Verfahren zur Behandlung von HCV mit wenigstens zwei direkt angreifenden viralen Mitteln, Ribavirin aber nicht Interferon.
US8492386B2 (en)	2011-10-21	2013-07-23	Abbvie Inc.	Methods for treating HCV
JP2015516423A (ja)	2012-05-07	2015-06-11	ノバルティスアーゲー	アリスポリビルによる薬物動態の調節
AR090964A1 (es) *	2012-05-09	2014-12-17	Novartis Ag	Proceso para la elaboracion de undecapeptidos ciclicos
WO2014085623A1 (en)	2012-11-28	2014-06-05	Enanta Pharmaceuticals, Inc.	Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues
US20140205566A1 (en)	2012-11-30	2014-07-24	Novartis Ag	Cyclic nucleuoside derivatives and uses thereof
WO2015008223A1 (en)	2013-07-17	2015-01-22	Novartis Ag	Treatment of hepatitis c virus infection with alisporivir and ribavirin
JP2016538317A (ja)	2013-08-26	2016-12-08	エナンタファーマシューティカルズインコーポレイテッド	Ｃ型肝炎を防止または治療するための新規シクロスポリン類似体
WO2015136455A1 (en)	2014-03-13	2015-09-17	Novartis Ag	New treatments of hepatitis c virus infection
US9669095B2 (en)	2014-11-03	2017-06-06	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues for preventing or treating hepatitis C infection
EA201892448A1 (ru)	2016-04-28	2019-06-28	Эмори Юниверсити	Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
CN110799523A (zh)	2017-05-12	2020-02-14	中外制药株式会社	用于制备环状有机化合物的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2757522B1 (fr) *	1996-12-24	1999-01-29	Rhone Poulenc Rorer Sa	Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) *	1996-12-24	1999-01-29	Rhone Poulenc Rorer Sa	Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
GB9811854D0 (en) *	1998-06-02	1998-07-29	Ciba Geigy Ag	Organic compounds
AU759480B2 (en) *	1998-07-01	2003-04-17	Debiopharm S.A.	Novel cyclosporin with improved activity profile
GB0320638D0 (en) *	2003-09-03	2003-10-01	Novartis Ag	Organic compounds

2005
- 2005-10-03 DK DK05791430.1T patent/DK1793844T3/da active
- 2005-10-03 PL PL05791430T patent/PL1793844T3/pl unknown
- 2005-10-03 AU AU2005290984A patent/AU2005290984B2/en not_active Ceased
- 2005-10-03 EA EA200700725A patent/EA012650B1/ru not_active IP Right Cessation
- 2005-10-03 UA UAA200704937A patent/UA88484C2/ru unknown
- 2005-10-03 RS RS20110108A patent/RS51614B/sr unknown
- 2005-10-03 JP JP2007534110A patent/JP4892486B2/ja not_active Expired - Fee Related
- 2005-10-03 HR HR20110169T patent/HRP20110169T1/hr unknown
- 2005-10-03 GE GEAP200510037A patent/GEP20104960B/en unknown
- 2005-10-03 KR KR1020077007285A patent/KR101191833B1/ko not_active Expired - Fee Related
- 2005-10-03 BR BRPI0515494-4A patent/BRPI0515494A/pt not_active IP Right Cessation
- 2005-10-03 PT PT05791430T patent/PT1793844E/pt unknown
- 2005-10-03 SG SG200800480-6A patent/SG139750A1/en unknown
- 2005-10-03 ES ES05791430T patent/ES2357587T3/es not_active Expired - Lifetime
- 2005-10-03 NZ NZ554412A patent/NZ554412A/en not_active IP Right Cessation
- 2005-10-03 MX MX2007003387A patent/MX2007003387A/es active IP Right Grant
- 2005-10-03 DE DE602005025232T patent/DE602005025232D1/de not_active Expired - Lifetime
- 2005-10-03 CA CA2580448A patent/CA2580448C/en not_active Expired - Fee Related
- 2005-10-03 CN CN2005800332843A patent/CN101056648B/zh not_active Expired - Fee Related
- 2005-10-03 SI SI200531225T patent/SI1793844T1/sl unknown
- 2005-10-03 WO PCT/IB2005/002940 patent/WO2006038088A1/en not_active Ceased
- 2005-10-03 AT AT05791430T patent/ATE490778T1/de active
- 2005-10-03 EP EP05791430A patent/EP1793844B1/de not_active Expired - Lifetime
2006
- 2006-04-12 US US11/406,800 patent/US7439227B2/en not_active Ceased
2007
- 2007-03-08 TN TNP2007000084A patent/TNSN07084A1/en unknown
- 2007-03-28 ZA ZA200702610A patent/ZA200702610B/xx unknown
- 2007-04-01 IL IL182362A patent/IL182362A0/en not_active IP Right Cessation
- 2007-04-27 MA MA29858A patent/MA28950B1/fr unknown
2008
- 2008-08-26 US US12/230,198 patent/US7772184B2/en not_active Expired - Fee Related
2010
- 2010-10-29 US US12/915,370 patent/USRE43371E1/en not_active Expired - Fee Related
2011
- 2011-03-08 CY CY20111100263T patent/CY1114594T1/el unknown

Also Published As

Publication number	Publication date
US7439227B2 (en)	2008-10-21
NZ554412A (en)	2011-01-28
CA2580448A1 (en)	2006-04-13
HK1104236A1 (en)	2008-01-11
JP4892486B2 (ja)	2012-03-07
EP1793844A1 (de)	2007-06-13
CN101056648A (zh)	2007-10-17
PL1793844T3 (pl)	2011-05-31
PT1793844E (pt)	2011-03-10
HRP20110169T1 (hr)	2011-04-30
CN101056648B (zh)	2012-08-15
DE602005025232D1 (de)	2011-01-20
EA200700725A1 (ru)	2007-10-26
RS51614B (sr)	2011-08-31
EA012650B1 (ru)	2009-12-30
CY1114594T1 (el)	2016-10-05
GEP20104960B (en)	2010-04-26
US7772184B2 (en)	2010-08-10
CA2580448C (en)	2012-09-18
SI1793844T1 (sl)	2011-05-31
US20060252675A1 (en)	2006-11-09
US20090081164A1 (en)	2009-03-26
ZA200702610B (en)	2008-08-27
DK1793844T3 (da)	2011-03-21
USRE43371E1 (en)	2012-05-08
MX2007003387A (es)	2007-05-23
KR20070073761A (ko)	2007-07-10
MA28950B1 (fr)	2007-10-01
AU2005290984A1 (en)	2006-04-13
WO2006038088A1 (en)	2006-04-13
AU2005290984B2 (en)	2010-09-09
BRPI0515494A (pt)	2008-07-29
JP2008514690A (ja)	2008-05-08
SG139750A1 (en)	2008-02-29
EP1793844B1 (de)	2010-12-08
TNSN07084A1 (en)	2008-06-02
IL182362A0 (en)	2007-07-24
UA88484C2 (ru)	2009-10-26
ES2357587T3 (es)	2011-04-27
KR101191833B1 (ko)	2012-10-16

Legal Events

Date

Code

Title

Description

2011-06-15

UEP

Publication of translation of european patent specification

Ref document number: 1793844

Country of ref document: EP

Publication	Publication Date	Title
ATE490778T1 (de)	2010-12-15	Verwendung von äd-mealaü3-äetvalü4-ciclosporin zur behandlung von hepatitis-c-infektion
ATE497775T1 (de)	2011-02-15	Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
WO2006033995A3 (en)	2006-06-01	Thiazolidin-4-ones having anti-hepatitis b activity
DE60119784D1 (de)	2006-06-22	Cyclische salen metall verbindungen als einfänger von sauerstoffradikalen und verwendbar als antioxidantien bei der behandlung und vorbeugung von krankheiten
EP1802650A4 (de)	2008-08-20	3-ether- und 3-thioether-substituierte ciclosporinderivate zur behandlung und prävention einer hepatitis-c-infektion
EA200870019A1 (ru)	2008-12-30	Лактамовые соединения и способы их применения
EA200700243A1 (ru)	2007-08-31	Способы лечения гепатита с
BR0011838A (pt)	2002-03-05	Elementos misturadores estáticos empilhados
PL384263A1 (pl)	2008-07-21	Wariant oksydazy moczanowej i jego zastosowanie
ATE456369T1 (de)	2010-02-15	Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
UA88463C2 (ru)	2009-10-26	Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
DE602005012276D1 (de)	2009-02-26	Verwendung von probiotischen bakterien zur herstellung von topischen zusammensetzungen zum schutz der haut
WO2007092645A3 (en)	2007-10-04	Novel hcv inhibitor combinations and methods
TW200640482A (en)	2006-12-01	Variant forms of urate oxidase and use thereof
DE60137978D1 (de)	2009-04-23	Zusammensetzung zur förderung des haarwachstums
ATE538790T1 (de)	2012-01-15	Scopolamin für die behandlung von depression und ängstlichkeit
WO2005121138A3 (en)	2009-03-05	Heterotricyclic compounds for use as hcv inhibitors
DE60015568D1 (de)	2004-12-09	Zusammensetzungen zur behandlung von viralen infektionen und verfahren dafür
WO2006034001A3 (en)	2006-11-23	Methods of treating hiv infection
DK1147088T3 (da)	2006-05-15	6-arylphenanthridiner med PDE-IV-inhiberende aktivitet
EA200601392A1 (ru)	2006-12-29	Способы и композиции для лечения липодистрофии
ATE443262T1 (de)	2009-10-15	Molekulardiagnoseverfahren und behandlung von demenz mit lewy-körperchen
DE60229624D1 (de)	2008-12-11	Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
WO2005046617A3 (en)	2005-08-11	Compositions and methods for reducing microbial induced apoptosis
CU20070072A7 (es)	2009-09-08	Uso de [d-meala]3-[etval]4-ciclosporina para el tratamiento de infección por hepatitis c y composición farmacéutica que comprende la [d-meala]3-[etval]4-ciclosporina